DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES (Q2035396): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR, Adding English summary) |
(Changed an Item) |
||
| Property / fund | |||
| Property / fund: European Regional Development Fund / rank | |||
Normal rank | |||
Revision as of 18:40, 8 June 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES |
Project in Italy financed by DG Regio |
Statements
5,714.0 Euro
0 references
11,428.0 Euro
0 references
50.0 percent
0 references
15 November 2016
0 references
7 December 2018
0 references
3 December 2018
0 references
TAKIS SRL
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
L'AZIENDA DI BIOTECNOLOGIE TAKIS PRODUCE IN MODO INNOVATIVO ED EFFICACE ANTICORPI MONOCLONALI PER CONTO PROPRIO E PER CONTO TERZI. SEBBENE MOLTO COMPETITIVA NEI PROTOCOLLI DI VACCINAZIONE, IL PROCESSO ATTUALE MANCA DI UN SISTEMA ROBOTIZZATO PER L (Italian)
0 references
THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR (English)
0 references
Identifiers
F83G17000640007
0 references